Tumor Glycomics Laboratory for Discovery of Pancreatic Cancer Markers

描述（由申请人提供）：胰腺癌是美国癌症死亡的第四大原因。2006年，32，180人将被诊断患有胰腺癌，31，180人将死于胰腺癌-每小时4名美国人。胰腺癌的1年和5年预后是所有癌症中最差的（分别为4%和1%）。这种疾病的高死亡率主要是由于缺乏早期诊断手段。因此，RFA应用的长期目标是将新开发的糖组学技术应用于胰腺癌血清标志物的开发。胰腺癌在某种程度上是独特的，因为可以直接收集含有来自癌症的分泌物的胰腺导管液，其很可能含有潜在的糖蛋白和糖脂生物标志物。胰腺癌和对照胰腺的这种液体的糖组学分析，加上胰腺组织的信息，包括糖转录组分析，将使我们能够专注于特定的糖缀合物作为来自胰腺癌患者血清中的潜在标志物。我们的胰腺癌肿瘤糖组学实验室代表了格鲁吉亚大学复杂碳水化合物研究中心的研究人员之间的合作，包括NCRR生物医学糖组学中心的成员，以及凤凰城TGen研究所的临床研究人员，他们是胰腺癌专家。目的：1.胰管液和对照组（包括胰腺炎患者）的糖组学分析（聚糖、糖蛋白和鞘糖脂分析）。2.胰腺癌、非疾病对照和表现出胰腺炎的胰腺的糖组学分析（聚糖、糖蛋白、鞘糖脂和糖转录组分析）。3.胰腺癌潜在血清标志物的鉴定和检测方法的建立。4.初步评价标志物的特异性和敏感性。TGen及其国际胰腺癌研究团队将参与样本的采集分析，该研究团队涉及全球26个机构，以及NCI胰腺癌EDRN。

DESCRIPTION (provided by applicant): Pancreatic cancer is the 4th leading cause of cancer deaths in the U.S. In 2006, 32,180 will be diagnosed with pancreatic cancer and 31,180 will die from it-4 Americans every hour. Pancreatic cancer has the worst 1 and 5 year prognosis of any cancer (4% and 1%, respectively). The high mortality rate for this disease is due mainly to the lack of a means for its early diagnosis. The long-term goal of this RFA application, therefore, is to apply newly developed glycomic technologies to the development of serum markers for pancreatic carcinoma. Pancreatic cancer is somewhat unique in that it is possible to directly collect pancreatic ductal fluid that contains secretions from the cancer which is very likely to contain potential glycoprotein and glycolipid biomarkers. Glycomic analysis of this fluid from pancreatic cancers and control pancreases, coupled with information from pancreatic tissues, including glycotranscriptome analysis, will enable us to focus on specific glyconjugates as potential markers in serum from pancratic cancer patients. Our Tumor Glycomics Laboratory for Pancreatic Cancer represents a collaboration between investigators at the Complex Carbohydrate Research Center at the University of Georgia, including members of the NCRR Center for Biomedical Glycomics, and clinical researchers at the TGen Institute, Phoenix, who are pancreatic cancer specialists. Aims: 1. Glycomic analysis (glycan, glycoprotein, and glycosphingolipid analyses) of pancreatic ductal fluid and controls, including patients with pancreatitis. 2. Glycomic analysis (glycan, glycoprotein, glycosphingolipid, and glycotranscriptome analyses) of pancreatic carcinoma, non-diseased controls, and pancreases exhibiting pancreatitis. 3. Identification of potential serum markers of pancreatic carcinoma and assay development. 4. Initial evaluation specificity and sensitivity of markers. Collection of specimens for analysis will involve TGen and its international Pancreatic Cancer Research Team that involves 26 institutions world-wide, as well as the NCI EDRN for Pancreatic Cancer.